- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05242835
Management of Sleeve Gastrectomy Failure Using Single-anastomosis Metabolic Surgery
Sleeve gastrectomy (SG) has become the most commonly performed weight loss surgery, accounting for 60% of all bariatric operations worldwide. While technically easier with less side-effects and nutritional risks than other operations, SG is also associated with a higher risk of failure (20 to 40%). In such case, the most effective option consists in adding an intestinal bypass called the Biliopancreatic Diversion with Duodenal Switch (BPD-DS). This surgery is, however, technically challenging and yields a significant risk of complications, nutritional deficiencies or gastro-intestinal side-effects. Recently, a simplified version of the Standard DS, called Single-Anastomosis Duodenoileal Switch (SADI-S) was endorsed by surgical societies as one of the approved bariatric procedures. There is currently no prospective or randomized data to support the effectiveness of this new procedure, especially as a revisional approach. The Overall Objective of this randomized controlled trial project is to establish the clinical benefits of the SADI-S as a revisional surgery after SG, while also considering critical issues related to sex and gender. The investigator Overall Hypothesis is that the SADI-S represents a relevant revisional option for weight loss and metabolic recovery in women and men suffering from severe obesity who had a previous SG. The investigator propose to address the following research question.
Research Question: What are the clinical effects of SADI-S compared to standard DS when used as a revisional procedure after SG, in patients with obesity? Participants who need revisional surgery after SG will be enrolled in a prospective, randomized, double-blind (patient-evaluator), non-inferiority trial comparing SADI-S vs DS. The primary outcome will be 12-month excess weight loss. Secondary outcomes will be perioperative complications, risk of malnutrition, quality of life and gastrointestinal side effects. The investigator hypothesize that SADI-S offers similar weight loss compared to standard DS, but a lower risk of complications and nutritional deficiencies.
With the increase in the number of bariatric operations performed worldwide and the recent endorsement of the SADI-S as a regular procedure, reliable clinical data are urgently needed. The present proposal will directly address this knowledge gap.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Quebec
-
Quebec City, Quebec, Canada, G1V 4G5
- Institut Universitaire De Cardiologie Et De Pneumologie De Québec
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- had sleeve gastrectomy a minimum of 18 months before
- still meet the NIH criteria for bariatric surgery (BMI≥35kg/m2 with major comorbidities or BMI≥40kg/m2) or patients with EWL<50% or significant weight regain (≥20%EWL)
Exclusion Criteria:
- general contra-indication for bariatric surgery
- BMI<35kg/m2
- pregnancy
- cirrhosis
- abnormal bowel habits including irritable bowel syndrome and inflammatory bowel disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: biliopancreatic diversion with duodenal switch
Patient randomized for a the standard duodenal switch as second stage surgery after a sleeve gastrectomy (100cm common channel and 150cm alimentary limb)
|
Standard duodenal switch as second stage surgery after a sleeve gastrectomy (100cm common channel and 150cm alimentary limb)
Other Names:
|
EXPERIMENTAL: Single-anastomosis duodeno-ileal anastomosis
Patient randomized for a single-anastomosis duodeno-ileal anastomosis as second stage surgery after a sleeve gastrectomy (250cm common channel)
|
Single-anastomosis duodeno-ileal anastomosis as second stage surgery after a sleeve gastrectomy (250cm common channel)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Excess weight loss
Time Frame: 12 month
|
Percentage of excess weight loss mobilized in response to surgery
|
12 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Peroperative complications
Time Frame: from baseline up to 60 months
|
Complications graded with Clavien classification
|
from baseline up to 60 months
|
Risk of malnutrition
Time Frame: from baseline to 60 months
|
Risk of malnutrition assessed through measurement of its risk being mild (albumin<35g\L), moderate (albumin<30g/L) or severe (albumin<25g/L)
|
from baseline to 60 months
|
Change in quality of life (SF-36)
Time Frame: from baseline to 60 months
|
36-item short form survey evaluating quality of life on a scale form 0 to 100
|
from baseline to 60 months
|
Change in quality of life (BAROS)
Time Frame: from baseline to 60 months
|
Bariatric Analyses and Reporting Outcomes System score form -7 to 9
|
from baseline to 60 months
|
Change in quality of life (QLaval)
Time Frame: from baseline to 60 months
|
Laval questionnaire evaluating quality of life on 6 aspects on a scale from 0 to 7
|
from baseline to 60 months
|
Gastro-intestinal side effects
Time Frame: from baseline to 60 months
|
Evaluation of gastro-intestinal side effects with the Gastro-Intestinal Quality of Life Index from 0 to 144
|
from baseline to 60 months
|
Change in nutritional status (calcium)
Time Frame: from baseline to 60 months
|
Change in nutritional status based on blood analysis of calcium (mmol/L)
|
from baseline to 60 months
|
Change in nutritional status (ferritin)
Time Frame: from baseline to 60 months
|
Change in nutritional status based on blood analysis of ferritin (ug/L)
|
from baseline to 60 months
|
Change in nutritional status (TIBC)
Time Frame: from baseline to 60 months
|
Change in nutritional status based on blood analysis of TIBC (umol/L)
|
from baseline to 60 months
|
Change in nutritional status (iron)
Time Frame: from baseline to 60 months
|
Change in nutritional status based on blood analysis of iron (umol/L)
|
from baseline to 60 months
|
Change in nutritional status (prealbumin)
Time Frame: from baseline to 60 months
|
Change in nutritional status based on blood analysis of prealbumin (g/L)
|
from baseline to 60 months
|
Change in nutritional status (transferrin)
Time Frame: from baseline to 60 months
|
Change in nutritional status based on blood analysis transferrin (g/L)
|
from baseline to 60 months
|
Change in nutritional status (vitamin A)
Time Frame: from baseline to 60 months
|
Change in nutritional status based on blood analysis of vitamin A (umol/L)
|
from baseline to 60 months
|
Change in nutritional status (vitamin D3)
Time Frame: from baseline to 60 months
|
Change in nutritional status based on blood analysis of vitamin D3 (nmol/L)
|
from baseline to 60 months
|
Change in nutritional status (parathormone)
Time Frame: from baseline to 60 months
|
Change in nutritional status based on blood analysis parathormone (ng/L)
|
from baseline to 60 months
|
Change in food intake
Time Frame: from baseline to 60 months
|
Evaluation of the change in food intake using a web-based food frequency questionnaire (kcal/day)
|
from baseline to 60 months
|
Change in eating behavior
Time Frame: from baseline to 60 months
|
Change of eating behavior using the Three-Factor Eating Questionnaire evaluating cognitive restraint of eating on a scale from 0 to 20, disinhibition on a scale from 0 to 16 and hunger on a scale from 0 to 15
|
from baseline to 60 months
|
Change in food addiction
Time Frame: from baseline to 60 months
|
Change of eating behavior using the Yale Food Addiction Scale that includes a "symptom count" scale from 0 to 7 reflecting the number of addiction-like criteria endorsed and a dichotomous evaluation that indicates whether a threshold of three or more "symptoms" plus clinically significant impairment or distress has been met
|
from baseline to 60 months
|
Change in binge eating behavior
Time Frame: from baseline to 60 months
|
Change of eating behavior using the Binge Eating scale from 0 to 46
|
from baseline to 60 months
|
Evolution of obesity related diseases
Time Frame: from baseline to 60 months
|
Remission rate for comorbidities, including T2D, hypertension, dyslipidemia, sleep apnea according to the ASMBS definition of outcomes reporting
|
from baseline to 60 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Laurent Biertho, MD, Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Second stage SADI
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Standard duodenal switch
-
Laval UniversityCentre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie...Recruiting
-
Reading Health SystemRecruiting
-
Värmland County Council, SwedenActive, not recruitingObesity | Metabolic Syndrome | Malnutrition | Surgery
-
McMaster UniversityNot yet recruiting
-
Laval UniversityJohnson & Johnson; Centre de Recherche de l'Institut Universitaire de Cardiologie...UnknownGastrectomy | Biliopancreatic Diversion With Duodenal SwitchCanada
-
Hospital Universitari de BellvitgeInstituto de Salud Carlos IIIEnrolling by invitationDiabetes Mellitus, Type 2 | Bariatric Surgery Candidate | Severe ObesitySpain
-
Medical College of WisconsinTerminatedObesity | Type-2 Diabetes MellitusUnited States
-
Göteborg UniversityHelse Sor-OstUnknownHypertension | Obesity | DiabetesNorway, Sweden
-
Laval UniversityCentre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie... and other collaboratorsRecruitingDiabetes | Bariatric Surgery CandidateCanada
-
Université de SherbrookeLaval UniversityCompletedType 2 Diabetes | ObeseCanada